open access

Vol 17, No 6 (2012)
Expert consensus statement
Published online: 2012-11-01
Submitted: 2012-09-11
Get Citation

Recommendations of the Spanish Societies of Radiation Oncology (SEOR), Nuclear Medicine & Molecular Imaging (SEMNiM), and Medical Physics (SEFM) on F-FDG PET-CT for radiotherapy treatment planning

Begoña Caballero Perea, Antonio Cabrera Villegas, José Miguel Rodríguez, María José Velloso, Ana María Vicente, Carlos Huerga Cabrerizo, Rosa Morera López, Luis Alberto Romasanta, Moisés Sáez Beltrán
DOI: 10.1016/j.rpor.2012.10.001
·
Rep Pract Oncol Radiother 2012;17(6):298-318.

open access

Vol 17, No 6 (2012)
Expert consensus statement
Published online: 2012-11-01
Submitted: 2012-09-11

Abstract

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a valuable tool for diagnosing and staging malignant lesions. The fusion of PET and computed tomography (CT) yields images that contain both metabolic and morphological information, which, taken together, have improved the diagnostic precision of PET in oncology. The main imaging modality for planning radiotherapy treatment is CT. However, PET-CT is an emerging modality for use in planning treatments because it allows for more accurate treatment volume definition. The use of PET-CT for treatment planning is highly complex, and protocols and standards for its use are still being developed. It seems probable that PET-CT will eventually replace current CT-based planning methods, but this will require a full understanding of the relevant technical aspects of PET-CT planning. The aim of the present document is to review these technical aspects and to provide recommendations for clinical use of this imaging modality in the radiotherapy planning process.

Abstract

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a valuable tool for diagnosing and staging malignant lesions. The fusion of PET and computed tomography (CT) yields images that contain both metabolic and morphological information, which, taken together, have improved the diagnostic precision of PET in oncology. The main imaging modality for planning radiotherapy treatment is CT. However, PET-CT is an emerging modality for use in planning treatments because it allows for more accurate treatment volume definition. The use of PET-CT for treatment planning is highly complex, and protocols and standards for its use are still being developed. It seems probable that PET-CT will eventually replace current CT-based planning methods, but this will require a full understanding of the relevant technical aspects of PET-CT planning. The aim of the present document is to review these technical aspects and to provide recommendations for clinical use of this imaging modality in the radiotherapy planning process.

Get Citation

Keywords

Radiotherapy planning; PET; PET-CT; CT; Delineation; Contouring

About this article
Title

Recommendations of the Spanish Societies of Radiation Oncology (SEOR), Nuclear Medicine & Molecular Imaging (SEMNiM), and Medical Physics (SEFM) on F-FDG PET-CT for radiotherapy treatment planning

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 17, No 6 (2012)

Pages

298-318

Published online

2012-11-01

DOI

10.1016/j.rpor.2012.10.001

Bibliographic record

Rep Pract Oncol Radiother 2012;17(6):298-318.

Keywords

Radiotherapy planning
PET
PET-CT
CT
Delineation
Contouring

Authors

Begoña Caballero Perea
Antonio Cabrera Villegas
José Miguel Rodríguez
María José Velloso
Ana María Vicente
Carlos Huerga Cabrerizo
Rosa Morera López
Luis Alberto Romasanta
Moisés Sáez Beltrán

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl